

Love Pharma Inc. (formerly Glenbriar Technologies Inc.)
Management's Discussion and Analysis
For the period ended March 31, 2022

DATE OF REPORT: May 26, 2022

This Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed consolidated financial statements of Love Pharma Inc. for the period ended March 31, 2022, and related notes attached thereto (the "financial statements"), which are prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts are expressed in Canadian dollars unless otherwise stated. References to notes are with reference to the financial statements. Readers may also want to refer to the December 31, 2021 audited consolidated financial statements.

This MD&A, may contain forward-looking statements, including statements regarding the business and anticipated future financial performance of the Company, which involve risks and uncertainties. These risks and uncertainties may cause the Company's actual results to differ materially from those contemplated by the forward-looking statements. Factors that might cause or contribute to such differences include, among others, share market price, continued availability of capital financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and those actual results or developments may differ materially from those projected in the forward-looking statements. Investors are also directed to consider other risks and uncertainties discussed in the Company's required consolidated financial statements and filings.

It is the Company's policy that all forward-looking statements, if any, are based on the Company's beliefs and assumptions which are based on information available at the time these assumptions are made. The forward-looking statements are subject to change, and the Company assumes no obligation to publicly update or revise the statements to reflect new events or circumstances, except as may be required pursuant to applicable laws. Although management believes that the expectations represented by such forward-looking information or statements are reasonable, there is significant risk that the forward-looking information or statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking information or statements contained in this MD&A, may include, but are not limited to, information or statements concerning management's expectations for the Company's ability to raise capital and meet its obligations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking information or statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors such as those described above and in "Risks and Uncertainties" below. The Company has no policy for updating forward-looking information beyond the procedures required under applicable securities laws.

DESCRIPTION OF BUSINESS

Love Pharma Inc. (formerly Glenbriar Technologies Inc.) ("Love Pharma" or the "Company") was incorporated under the Alberta Business Corporations Act on July 15, 1994 and is a publicly traded company listed on the Canadian Securities Exchange ("CSE") (trading symbol: LUV). The Company is a licensee of certain technologies relating to cannabinoids ("CBD") and psilocibin.

On September 20, 2021, the Company changed its name to Love Pharma Inc. from Glenbriar Technologies Inc. The head office of the Company is located at Suite 1780 – 355 Burrard Street Vancouver, British Columbia, V7X 1B1. The registered office of the Company is located at 250 Howe Street, 20th Floor, Vancouver, BC, V6C 3R8.

The Company's website is <https://love-pharma.com/>.

On September 22, 2021, the Company acquired 100% of the issued and outstanding common shares of Kick Pharmaceutical Inc. ("Kick") in exchange for 183,067,857 of the Company's common shares. The acquisition was accounted for as a reverse takeover ("RTO") whereby Kick obtained a listing of its shares on the CSE.

In addition, the Company entered into an arm's-length purchase and sale agreement with 1288339 BC Ltd. dated March 5, 2021 pursuant to which the Company agreed to acquire all of the issued and outstanding shares of 1288339 BC Ltd. by the issuance of 20,000,000 Common Shares at a deemed price of \$0.10 (a fair value of \$0.06 for accounting purposes).

The Company issued 3,000,000 common shares to Callitas Therapeutics Inc. (“Callitas”) (listed under the symbol LILY on the CSE) pursuant to two license agreements entered into between 1288339 BC Ltd. and Callitas and 2122774 Alberta Ltd and Callitas. This transaction closed concurrently with the RTO.

Immediately following the RTO and acquisition of 1288339 BC Ltd., the former shareholders of Kick held approximately 58% of the issued and outstanding common shares of the Company, the original shareholders of the Company held approximately 36% and the shareholders of 1288339 BC Ltd. held approximately 6%.

Effective September 30, 2021, the Company consolidated its common shares on a 2:1 basis. All share and per share amounts in the consolidated financial statements have been retroactively restated to reflect the share consolidation.

ACQUISITION OF KICK

On September 22, 2021, the Company issued 183,067,857 common shares to the shareholders of Kick. As a result, the shareholders of Kick acquired control of Love Pharma, thereby constituting a reverse takeover of Love Pharma. The transaction is considered a purchase of Love Pharma’s net assets by the Kick shareholders. The transaction is accounted for in accordance with guidance provided in IFRS 2, Share-Based Payment, as Love Pharma did not qualify as a business according to the definition in IFRS 3, Business Combinations.

The transaction is recognized as if Kick had issued common shares to the existing Company shareholders outstanding before the transaction in exchange for the net assets acquired. The fair value of the 108,851,997 common shares of Love Pharma was determined to be \$0.06 per common share, based on the fair value as determined by reference to the concurrent financing. The fair value of the 35,779,333 warrants were valued at \$167,200 using the Black-Scholes option pricing model using a weighted average exercise price of \$0.145, a 100% volatility rate, a 0.44% risk free return, and a 0.60 year term.

The resulting consolidated statement of financial position is presented as a continuance of Kick and comparative figures presented in the consolidated financial statements prior to the reverse takeover are those of Kick.

IFRS 2 applies to transactions where an entity grants equity instruments and cannot identify specifically some or all of the goods or services received in return. Because Kick issued shares with a fair value in excess of the assets received, the difference is recognized in profit or loss as a share listing expense. The amount assigned to the share listing expense of \$6,048,225 is the difference between the fair value of the consideration and the net identifiable assets of Love Pharma acquired by Kick.

The fair value of the net assets (liabilities) acquired from Love Pharma as at September 22, 2021 are:

Consideration paid:	
Fair value of 108,851,997 Love Pharma common shares	\$ 6,531,125
Fair value of 35,779,333 Love Pharma warrants	167,200
Total consideration paid	\$ 6,698,325
Identifiable assets acquired:	
Cash	\$ 24,255
Prepays	250,000
Investments	717,142
Trade and other payables	(44,220)
Loan payable	(290,273)
GST liability	(6,804)
Net assets acquired	650,100
Unidentifiable assets acquired:	
Share listing expense	6,048,225
Total net identifiable assets and share listing costs	\$ 6,698,325

Love Pharma is currently a life sciences issuer, and its primary focus is: (i) the development of wellness products and the completion of manufacturing arrangements, marketing channels and advertising to drive sales of its primary wellness products into markets in the United Kingdom and the European Union; and (ii) the development of innovative drug delivery systems.

Love Pharma's Wellness Product Portfolio business segment is currently comprised of the portfolio of wellness products and the underlying intellectual property, concentrating on sexual health, with or without the benefit of CBD, acquired pursuant to the Product License. In particular, the Company has rights to utilize the following products and the related intellectual property pursuant to the Product License:

CBD oral strips (CannaStrips™): CannaStrip™ oral muco-adhesive strips enhance the bioavailability of hemp oil extracts and THC, increasing the impact and duration of the health benefits. CannaStrip™ delivers hemp oil extracts and THC faster, with longer beneficial effects in the body.

Arouse RX gel with CBD and/or THC (Arousel Gel): The Arousel Gel is a topical gel infused with CBD and/or THC that increases genital blood flow causing vaginal engorgement/lubrication and clitoral engorgement/sensitivity. This stimulation arouses the user, addressing female sexual dysfunction issues. The Arousel Gel can also be sold as a product without CBD and THC.

CBD/THC biphasic mints/candies (CannaMint): CannaMint is a patent-protected technology that uses orally dissolvable mints to deliver CBD or THC for a variety of conditions. These CannaMints increase the onset of actives when compared to edible consumption and do not have the negative impacts associated with smoking. They are discreet and sublingual with a minty flavor.

Female Sexual Dysfunction supplement (FSD Supplement): The FSD Supplement is a clinically proven female sexual desire supplement that utilizes known and approved ingredients to increase the active, free testosterone in women, which is directly aligned with sexual responsiveness and arousal in women.

ToConceive: ToConceive is an innovative, FDA-cleared, multi-patented vaginal moisturizer that improves the ability to conceive naturally. ToConceive is not a traditional lubricant; it is a gel, moisturizer, and a lubricant. When applied to the vulva and clitoris daily, ToConceive helps the body produce additional lubrication that helps sperm fertilize an egg.

Male Enhancement Gel With CBD (Male Enhancement Gel): The Male Enhancement Gel is a topical personal care penile gel containing proprietary levels of L-arginine and menthol increasing penis length, girth, and volume (overall size).

Partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder.

OUTLOOK

Love Pharma specializes in mental health and sexual wellness by licensing and distributing psychedelic and hemp-infused products.

Love Parma has exclusive rights/licenses to produce, market, package, sell and distribute 6 pharmaceutical and therapeutic products throughout Europe, North America and the United Kingdom.

The Company is working with partners are currently developing a biosynthetic psilocybin-infused oral strip using our existing intellectual property developed for the mucoadhesive CBD strip.

OPERATIONAL HIGHLIGHTS

September 29, 2021 – Love Pharma Inc. (CSE: LUV) (the “Company”) announced that it has changed its name, has completed the arm’s-length acquisition of all of the shares of private BC-based Kick Pharmaceuticals, Inc., and has affected a two for one share consolidation.

October 6, 2021 – the Company announced the appointment of Joshua Maurice as its Chief Operating Officer. Joshua has 20 years of experience in consumer goods with a focus on the development of over-the-counter drug and nutraceuticals, including efficacy, clinical research, branding, marketing, advertising, and global retail distribution.

October 12, 2021 – the Company announced that its common shares were accepted for listing on the Frankfurt Stock Exchange (FSE) under the trading symbol “G1Q0”.

October 20, 2021 - the Company has announced that it is developing a muco-adhesive sublingual strip. The Company is partnering with the strip’s creator, a US based pharmaceutical company, to develop it for use as a psilocybin delivery system.

October 27, 2021 – the Company announced the launch of two fully-branded products, Bloom and Auralief.

November 23, 2021 – the Company has executed a Letter of Intent (“LOI”) to acquire 100% of MicroDoz Therapy Inc. (“MicroDoz”), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder.

LIQUIDITY

Subsequent to March 31, 2022, the Company completed the first tranche of a non-brokered private placement for 16,550,000 units at a price of \$0.02 per unit for gross proceeds of \$331,000. Each unit consists of one common share and one common share purchase warrants. Each warrant entitles the holder to purchase one additional common share at \$0.05 for a period of 2 years from the date of closing. The Company paid \$9,050 in finders’ fees and issued 400,000 broker warrants on the same terms of the unit warrants.

CASH FLOWS

During the period ended March 31, 2022, the Company had:

- i) net cash used in operating activities of \$327,528 which consisted primarily of costs associated with operating costs.
- ii) net cash provided by financing activities of \$210,000, which consisted of cash received from subscriptions received in advance.

SELECTED QUARTERLY RESULTS

A summary of selected information for each of the quarters is as follows:

Three Months Ended	Revenues	Comprehensive Gain (Loss)	Basic and Diluted Earnings (Loss) Per Share
March 31, 2022	\$-	\$ (253,881)	\$ (0.00)
December 31, 2021	-	(2,831,572)	(0.01)
September 30, 2021	-	(6,341,637)	(0.03)
June 30, 2021	-	(194,749)	(0.00)
March 31, 2021	-	(153,197)	(0.00)
December 31, 2020	-	(91,249)	(0.00)
September 30, 2020	-	(39,574)	(0.00)
June 30, 2020	-	(26,709)	(0.00)

Three months ended March 31, 2022 vs 2021

The Company's loss and comprehensive loss totaled \$253,881 for the three month period ended March 31, 2022 (2021 - \$165,058), with basic and diluted loss per share of \$0.00 (2021 - \$0.00). Significant fluctuations during the three months were primarily a result of increased activities post RTO and impairment of intangible assets. Figures prior to the completion of the Kick RTO are that of Kick, which was a private company prior to the RTO.

- i) Advertising and promotion of \$78,735 (2021 - \$Nil) increased due to the Company's effort to increase market awareness during the current period.
- ii) Consulting and management fees of \$79,910 (2021 - \$54,434) increased due to fee paid to CEO and CFO during the current period.
- iii) Professional fees of \$52,882 (2021 - \$98,856) decreased due to increase in legal activities setting up the Kick agreement during the prior period.
- iv) Transfer agent and filing fees of \$9,398 (2021 - \$Nil) increased due to filing of RTO documents in current period.
- v) Travel and entertainment of \$8,887 (2021 - \$Nil) increased due to additional travel taken by management during the current period.

Cash and Working Capital

As at March 31, 2022, the Company had cash of \$217,253 (December 31, 2021 - \$334,781) and a working capital deficiency of \$8,462 (December 31, 2021 - \$201,189).

OUTSTANDING SHARE DATA

Authorized Share Capital

The Company is authorized to issue an unlimited number of common shares without par value. All issued common shares are fully paid.

As at the date of this MD&A, the Company had 331,469,854 common shares outstanding, 90,576,129 warrants outstanding and 19,250,000 options outstanding.

OFF BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Details of outstanding balances with related parties including key management personnel are as follows:

Transactions with related parties and key management personnel are as follows:

	Nature of transactions	Period ended March 31, 2022	Year ended December 31, 2021
Paid or accrued to the CEO and director	Consulting fees	\$ 30,000	\$ 91,700
Paid or accrued to a director	Consulting fees	\$ 2,100	\$ 8,100
Paid or accrued to the COO	Consulting fees	\$ 32,810	\$ 110,587
Fair value of options granted to officers and directors	Share-based compensation	\$ -	\$ 236,623
		\$ 64,910	\$ 447,010

The amounts for key management personnel are as follows:

	March 31, 2022	December 31, 2021
Due to directors, included in accounts payable and accrued liabilities	\$ 700	\$ 700-
Prepayment of fees to a director, included in prepaids	\$ -	\$ 10,710

The amounts due to related parties are unsecured, non-interest bearing and are due on demand.

SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS

Please refer to the Notes on the condensed consolidated financial statements for the period ended March 31, 2022.

FINANCIAL INSTRUMENTS

Please refer to the Notes on the condensed consolidated financial statements for the period ended period ended March 31, 2022.

RISK FACTORS

Fair value of financial instruments

The Company's financial instruments are comprised of cash, note receivable, investments, accounts payable and accrued liabilities and loans payable. The carrying values of the Company's cash, note receivable, accounts payable and accrued liabilities and loans payable approximate their respective fair values due to their short term to maturity.

Financial instruments recorded at fair value on the statement of financial position are classified using a fair value hierarchy that reflects the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 reflects valuation based on quoted prices observed in active markets for identical assets or liabilities.
- Level 2 reflects valuation techniques based on inputs that are quoted prices of similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; inputs other than quoted prices used in a valuation model that are observable for that instrument; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 reflects valuation techniques with significant unobservable market inputs.

The Company's investment in Eleos is classified as Level 3 and its investment in LHG is classified as Level 1.

Credit risk

Credit risk is the risk of financial loss associated with the counterparty's inability to fulfill its payment obligations. The Company is satisfied with the credit ratings of its bank. As at March 31, 2022 the Company believes it has no significant credit risk associated with cash or note receivable. The Company's exposure to credit risk is the carrying value of the respective financial assets.

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at March 31, 2022 the Company had a cash balance of \$217,253 (December 31, 2021 - \$334,781) to settle accounts payable and accrued liabilities of \$302,189 (December 31, 2021 - \$259,436) and loans payable of \$226,246 (December 31, 2021 - \$223,677). The Company will require financing from lenders, shareholders and other investors to generate sufficient capital to meet its short-term business

requirements. The Company's trade payables have contractual maturities of 30 days and are subject to normal trade terms, the loans payable are due within 12 months or on demand.

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, commodity and equity prices.

Foreign exchange risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. As at March 31, 2022, the Company was not exposed to any significant foreign currency risk.

Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company believes it has no significant interest rate risk as cash balances are held in accounts which earn nominal interest and notes receivable and loans payable have fixed rates of interest.

Price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company is not exposed to material price risk at March 31, 2022.

Capital management

The Company manages its capital structure to maximize its financial flexibility making adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets and business opportunities. The Company does not presently utilize any quantitative measures to monitor its capital and is not subject to externally imposed capital requirements. The Company's strategy for capital management did not change during the period ended March 31, 2022.

RISKS AND UNCERTAINTIES

The Company is a health and wellness pharmaceutical company and is exposed to a number of risks and uncertainties that are not uncommon to other companies in the same business. The Company has no ongoing revenue or income from operations. The Company has limited capital resources and has to rely upon the sale of its assets, sale of its common shares or issuance of debt for cash required to make new investments and to fund the administration of the Company. These risks may not be the only risks faced by the Company.

Additional risks and uncertainties not presently known by the Company or which are presently considered immaterial may also adversely impact the Company's business, results of operations, and financial performance. The most significant risks and uncertainties faced by the Company are (in no specific order):

Limited Operating History

The Company has limited operating history in the pharmaceuticals industry. The Company and its business prospects must be viewed against the background of the risks, expenses and problems frequently encountered by companies in the early stages of their development, particularly companies in new and rapidly evolving markets.

Regulatory

In all jurisdictions where CBDs, psilocybin or THC are part of the wellness products, regulatory approval needs to be addressed. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the business, results of operations and financial condition of the Company.

The Company's operations are subject to a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of its products but also including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. To its knowledge, the Company is currently in compliance with such laws in all material respects. Changes to such laws, regulations and guidelines due to matters beyond the control of the Company may cause adverse effects to the Company's operations.

As a manufacturer and distributor of products designed to be ingested by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury.

There is no certainty that the Company will be able to operate profitably.

Competition

The Company will compete with numerous other businesses in the medical and adult use industry, many of which possess greater financial and marketing resources and other resources than the Company.

No Profits to Date

The Company has not made profits and it is expected that it will not be profitable for the foreseeable future. Its future profitability will, in particular, depend upon its success in making strategic investments in health and wellness. Because of the limited operating history, and the uncertainties regarding the development of the health and wellness market there are significant risks associated with the Company's investment strategy.

Additional Requirements for Capital

Substantial additional financing may be required if the Company is to be successful in developing distribution of products from current licences. No assurances can be given that the Company will be able to raise the additional capital that it may require for its anticipated future development. Any additional equity financing may be dilutive to investors and debt financing, if available, may involve restrictions on financing and operating activities. There is no assurance that additional financing will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations or anticipated investments.

Dependence on Management Team

The Company currently depends on certain key senior managers to identify business opportunities and acquisitions. Management who have developed key relationships in the industry are also relied upon to oversee the core marketing, business development, operational and fundraising activities. The Company expects the competition for management and other skilled personnel to intensify. Competition for experienced senior management is intense and other companies with greater financial resources may offer a higher and more attractive compensation package to recruit our senior managers. If one or more of our senior managers are unable or unwilling to continue their positions with the Company, we may not be able to replace them easily. Failure to attract and retain qualified employees or the loss or departure in the short-term of any member of the senior management may result in a loss of organizational focus, poor operating execution or an inability to identify and execute potential strategic initiatives. This could, in turn, materially and adversely affect the Company's business, financial condition and results of operations.

Risks associated with Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant effects on the world's equity markets and the movement of people and goods has become restricted. Due to market uncertainty, the Company may be restricted in its ability to raise additional funding. The impact of these factors on the Company is not yet determinable; however, they may have a material impact on the Company's financial position, results of operations and cash flows in future periods. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company and its operations in future periods.